AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ROIV · NASDAQ · Biotechnology

Roivant Sciences

Develops immunology medicines and delivery technologies through focused Vant subsidiaries.

$34.44

After-hours close−0.25 (−0.72%)

At close$34.69(−7.69%)

Something off on this page? Send us feedback.

Profile

Roivant Sciences Ltd.ROIVHealth Care

Develops medicines and delivery technologies through focused Vant subsidiaries, with retained programs in autoimmune and inflammatory disease plus Genevant's lipid-nanoparticle platform. With no commercial-stage product at the latest fiscal year-end, economics depend on clinical outcomes, regulatory approvals, ownership, licensing, and patent rights.

Develops medicines and drug-delivery technologies through focused subsidiaries called Vants, which operate like independent biotechnology companies while sharing a broader platform. The retained portfolio centers on Priovant’s brepocitinib, Immunovant’s IMVT-1402, Pulmovant’s mosliciguat, and Genevant’s lipid-nanoparticle technology and patent interests.

Clinical work is concentrated in autoimmune and inflammatory disease. The workforce is concentrated in the United States, while principal offices are listed in London, New York, and Basel.

No retained commercial-stage product was present at the latest fiscal year-end. Economics therefore depend on clinical outcomes, regulatory approvals, future commercialization, ownership and licensing terms, while Genevant also depends on patent rights, settlement allocation, and an appellate contingency.

Company facts

CEOMatthew Gline

ListedOct 1, 2021

ExchangeNASDAQ

HeadquartersNew York, NY

CountryUnited Kingdom

Employees721

CIK0001635088

ISINBMG762791017

Key statistics

Market cap$25.07B

EPS (ttm)−$0.4400

P/E (ttm)−78.89

ROE-6.1%

P/B5.91

P/S3,329.09

Dividend yield—

Beta1.11vs XLV 0.46

Year to date +58.2% · Average volume (30d) 5.4M

Analysts

Price target, next 12 months$41.00+18.1%Median of 15 analysts · vs the Aug 28 close

ConsensusBuy14 of 15 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $34.71

High$42.00+21.0%

Median$41.00+18.1%

Low$36.00+3.7%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 7, 2026	H.C. Wainwright	Reiterate	Buy	$34	$41
May 26, 2026	Guggenheim	Reiterate	Buy	$30	$36
May 21, 2026	Cowen & Co.	Target			$41
May 21, 2026	Leerink Partners	Target		$32	$42
Apr 16, 2026	Piper Sandler	Reiterate	Overweight	$20	$40

Earnings

EPS

Estimate−$0.41

ReportedDue Nov 9, 2026

Revenue

Estimate$3.9M

ReportedDue Nov 9, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q1 FY26	−$0.30	−$0.33	−10.1%	$2.1M	$1.4M	−29.9%	+1.50%
May 20, 2026Q4 FY25	−$0.29	−$0.28	+3.5%	$3.4M	$2.5M	−26.2%	−4.72%
Feb 6, 2026Q3 FY25	−$0.30	−$0.24	+19.9%	$5.1M	$2.0M	−60.6%	+7.16%
Nov 10, 2025Q2 FY25	−$0.32	−$0.28	+12.4%	$5.6M	$1.6M	−72.0%	−1.28%

View details

Financial highlights

	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26
Revenue	$7.6M	$2.2M	$1.6M	$2.0M	$2.5M	$1.4M
Gross profit	$7.4M	$2.0M	$1.5M	$1.3M	$2.2M	$1.2M
Operating income	−$285.0M	−$284.9M	−$306.2M	−$339.2M	−$355.0M	−$366.0M
Net income	−$206.5M	−$223.4M	−$113.5M	−$265.9M	$303.0M	−$189.8M
Diluted EPS	−$0.29	−$0.33	−$0.17	−$0.38	$0.37	−$0.26
Gross margin	97.3%	92.9%	92.9%	65.0%	87.3%	80.3%
Operating margin	-3,764.4%	-13,130.0%	-19,492.9%	-16,966.1%	-14,087.1%	-25,380.9%

Fiscal years (4-quarter sums)FY23 $69.8M · FY24 $29.1M · FY25 $8.3M

Revenue by product · Q1 FY26

Reportable Segment$1.4M · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $3.84B · Total debt $107.2M · Total assets $5.31B · Shareholders' equity $4.23B

Dividends

No dividends on record.

Ownership

Institutions 79.97%577.70M sharesInsiders 10.45%75.50M sharesOther 9.58%69.20M shares

Shares outstanding 722.41M · Float 577.47M · 79.9% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
FMR LLC	81.02M	11.22%	13F	Aug 13, 2026
BlackRock, Inc.	48.24M	6.68%	13F	Aug 7, 2026
Ramaswamy Vivek · 10 percent owner	47.01M	6.51%	Form 4	Dec 15, 2025
Morgan Stanley	42.59M	5.90%	13F	Aug 13, 2026
QVT Financial LP	23.72M	3.28%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 21, 2026	Mayukh Sukhatme	director, officer: President & CIO	−144,756	$36.48
Aug 20, 2026	Mayukh Sukhatme	director, officer: President & CIO	−17,519	$37.30
Aug 19, 2026	Mayukh Sukhatme	director, officer: President & CIO	−172,899	$37.17
Aug 18, 2026	Mayukh Sukhatme	director, officer: President & CIO	−136,942	$36.73
Aug 17, 2026	Mayukh Sukhatme	director, officer: President & CIO	−284,707	$36.25